Laboratory Corporation of America Holdings(NYSE: LH) operates in a dynamic business landscape, marked by operational changes, acquisitions, and strategic partnerships. Notably, the corporation's position was reduced by American International Group Inc and sold by Shell Asset Management Co. Despite these, novel investments poured in, such as the $282,000 investment by CreativeOne Wealth LLC and the $1.29 Million by Seven Eight Capital LP. LH extended its portfolio by securing winning bids for assets of Invitae and BioReference Health's Diagnostics Business. The last five-year investment in LH has yielded an impressive 67% increase. Also, LH shares were acquired by Quadrature Capital Ltd. The company's earnings per share missed expectations in 2023 while beating revenue expectations in the first quarter of 2024. It boosted clinical diagnostics with a new deal and introduced a Weight Loss Management Portfolio. The laboratory company also branched out launching 'Fortrea' its independent clinical development business. LH stands out as a holder of a moderate buy consensus rating. Lastly, various firms such as QRG Capital Management Inc., and Councilmark Asset Management LLC increased their stakes in LH.
Laboratory Corporation of America Holdings LH News Analytics from Fri, 29 Jul 2022 07:00:00 GMT to Sun, 28 Jul 2024 18:01:33 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -1
